Breaking News Instant updates and real-time market news.

AGN

Allergan

$189.49

-4.81 (-2.48%)

, MYL

Mylan

$36.61

0.55 (1.53%)

14:52
12/01/16
12/01
14:52
12/01/16
14:52

Allergan CEO: Trump to be 'vicious' against next price scandal, Bloomberg says

Speaking at the Forbes Healthcare Summit Thursday, Allergan (AGN) CEO Brent Saunders said President-elect Donald Trump will be "more vicious" in attacking the next pharmaceutical price controversy, reports Bloomberg. "I worry today that the pharmaceutical industry has a very false sense of relief or security because of a Trump administration and Republican-controlled Congress. To think that President-elect Trump isn't a populist, that he won't jump on the next EpiPen scandal and tweet more than Hillary Clinton tweeted or anyone else, because he's a prolific tweeter, you're fooling yourself... The next big scandal will revive the debate and probably then some. [Trump] will be more vicious, more focused, on taking down whoever does something again," Saunders said, according to Bloomberg. The report notes that companies including Mylan (MYL) and Valeant (VRX) have come under fire for drug price hikes, adding that the hearing that brought Mylan CEO Heather Bresch to D.C. was called by Republicans. Reference Link

AGN

Allergan

$189.49

-4.81 (-2.48%)

MYL

Mylan

$36.61

0.55 (1.53%)

VRX

Valeant

$15.42

-0.37 (-2.34%)

  • 01

    Dec

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

  • 28

    Mar

AGN Allergan
$189.49

-4.81 (-2.48%)

11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
MYL Mylan
$36.61

0.55 (1.53%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/26/16
10/26/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL) initiated with a Buy at Mizuho. 2. Five Below (FIVE) initiated with a Buy at Longbow. 3. NetSuite (N) reinstated with an Underperform at BofA/Merrill. 4. Adient (ADNT) initiated with a Buy at Northcoast. 5. Party City (PRTY) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/16
MZHO
10/25/16
INITIATION
Target $49
MZHO
Buy
Mylan initiated with a Buy at Mizuho
Mizuho analyst Irina Koffler initiated Mylan with a Buy and a $49 price target.
10/10/16
10/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VRX Valeant
$15.42

-0.37 (-2.34%)

11/30/16
WELS
11/30/16
NO CHANGE
WELS
Underperform
Wells says SEC correspondence reveals possible issues with Valeant accounting
Wells Fargo analyst David Maris said a series of letters made available by the SEC today reveal that the regulator has been questioning Valeant over its tax reporting and disclosures. The letters also make it appear that Valeant will be presenting new measures and disclosures with its Q4 results and 2017 guidance based on SEC concerns with its use of non-GAAP metrics, noted Maris. The analyst, who also called the report of a breakdown in Valeant's sale talks with Takeda around Salix "disappointing," keeps an Underperform rating and $10-$13 price target range on Valeant shares.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$117.81

-0.949 (-0.80%)

12:54
04/27/17
04/27
12:54
04/27/17
12:54
Hot Stocks
FDA expands approved use of Stivarga to treat liver cancer »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 26

    Jun

FB

Facebook

$146.56

0.07 (0.05%)

, LYV

Live Nation

$32.07

0.01 (0.03%)

12:54
04/27/17
04/27
12:54
04/27/17
12:54
Periodicals
Facebook tests improved concert tour feature with Live Nation, The Verge says »

Facebook (FB) is working…

FB

Facebook

$146.56

0.07 (0.05%)

LYV

Live Nation

$32.07

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

  • 08

    May

  • 16

    May

PENN

Penn National

$18.96

0.21 (1.12%)

12:51
04/27/17
04/27
12:51
04/27/17
12:51
Recommendations
Penn National analyst commentary  »

Penn National selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

LUV

Southwest

$55.41

-1.5263 (-2.68%)

12:51
04/27/17
04/27
12:51
04/27/17
12:51
Hot Stocks
Southwest sees FY17 fuel cost per gallon $1.95-$2.00 »

Backs FY17 CapEx view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MU

Micron

$26.79

-0.2 (-0.74%)

12:51
04/27/17
04/27
12:51
04/27/17
12:51
Options
Defensive option play opened in Micron »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 15

    May

  • 30

    May

  • 31

    May

  • 01

    Jun

  • 07

    Jun

GM

General Motors

$34.18

-0.205 (-0.60%)

, F

Ford

$11.38

-0.22 (-1.90%)

12:47
04/27/17
04/27
12:47
04/27/17
12:47
Earnings
On The Fly: What to watch in General Motors earnings report »

General Motors (GM) is…

GM

General Motors

$34.18

-0.205 (-0.60%)

F

Ford

$11.38

-0.22 (-1.90%)

FCAU

Fiat Chrysler

$11.20

-0.455 (-3.91%)

PUGOY

Peugeot

$20.65

0.1 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 02

    May

LUV

Southwest

$55.28

-1.66 (-2.92%)

12:47
04/27/17
04/27
12:47
04/27/17
12:47
Hot Stocks
Southwest sees Q2 RASM up 1%-2% »

Says no change in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SBUX

Starbucks

$61.56

0.6 (0.98%)

12:46
04/27/17
04/27
12:46
04/27/17
12:46
Technical Analysis
Starbucks trades at 52-week high, technical notes before earnings »

The shares were last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 24

    May

12:45
04/27/17
04/27
12:45
04/27/17
12:45
General news
Treasury 7-year auction preview: the sale is caught in the crosscurrents »

Treasury 7-year auction…

12:41
04/27/17
04/27
12:41
04/27/17
12:41
Options
Opening interest in WisdomTree India ETF options »

Opening interest in…

TSLA

Tesla

$310.17

-3.62 (-1.15%)

12:39
04/27/17
04/27
12:39
04/27/17
12:39
Periodicals
Tesla CEO holds one-on-one meeting with Chinese official, Fortune says »

Tesla CEO Elon Musk made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

PX

Praxair

$125.35

0.24 (0.19%)

12:37
04/27/17
04/27
12:37
04/27/17
12:37
Hot Stocks
Breaking Hot Stocks news story on Praxair »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

CAR

Avis Budget

$31.70

0.86 (2.79%)

12:36
04/27/17
04/27
12:36
04/27/17
12:36
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 10

    May

  • 16

    May

CMCSA

Comcast

$38.79

0.3 (0.78%)

, CMCSK

Comcast

12:34
04/27/17
04/27
12:34
04/27/17
12:34
General news
On The Fly: Top stock stories at midday »

Stocks began the session…

CMCSA

Comcast

$38.79

0.3 (0.78%)

CMCSK

Comcast

F

Ford

$11.42

-0.185 (-1.59%)

DOW

Dow Chemical

$63.30

-1.03 (-1.60%)

PYPL

PayPal

$44.41

-0.3 (-0.67%)

UPS

UPS

$108.63

1.005 (0.93%)

UAA

Under Armour

$21.55

1.835 (9.31%)

UA

Under Armour

$19.66

1.5201 (8.38%)

DPZ

Domino's Pizza

$186.50

5.54 (3.06%)

LUV

Southwest

$55.03

-1.91 (-3.35%)

AAL

American Airlines

$46.40

-0.21 (-0.45%)

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

TSLA

Tesla

$310.17

-3.62 (-1.15%)

, DDAIF

Daimler AG

$74.57

-0.6001 (-0.80%)

12:31
04/27/17
04/27
12:31
04/27/17
12:31
Periodicals
Grohmann removed from Tesla after clash with Musk, Reuters says »

Tesla (TSLA) executive…

TSLA

Tesla

$310.17

-3.62 (-1.15%)

DDAIF

Daimler AG

$74.57

-0.6001 (-0.80%)

BAMXY

BMW Group

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

HLT

Hilton

$60.02

-0.58 (-0.96%)

12:31
04/27/17
04/27
12:31
04/27/17
12:31
Initiation
Hilton initiated  »

Hilton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

PX

Praxair

$124.68

-0.43 (-0.34%)

12:30
04/27/17
04/27
12:30
04/27/17
12:30
Hot Stocks
Soroban Capital reports new 6.2% passive stake in Praxair »

Earlier today, Praxair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

WFM

Whole Foods

$36.35

0.29 (0.80%)

12:28
04/27/17
04/27
12:28
04/27/17
12:28
Periodicals
Neuberger Berman urges Whole Foods to explore sale, WSJ says »

Investment manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

INTC

Intel

$36.93

0.06 (0.16%)

12:27
04/27/17
04/27
12:27
04/27/17
12:27
Technical Analysis
Intel technical notes ahead of earnings, potential bullish pattern »

The shares are trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

SNAP

Snap

$21.76

0.175 (0.81%)

12:26
04/27/17
04/27
12:26
04/27/17
12:26
Options
Snap Inc. call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

WFM

Whole Foods

$36.35

0.29 (0.80%)

12:25
04/27/17
04/27
12:25
04/27/17
12:25
Periodicals
Breaking Periodicals news story on Whole Foods »

Neuberger Berman urges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

TAL

TAL Education

$119.61

3.43 (2.95%)

12:22
04/27/17
04/27
12:22
04/27/17
12:22
Recommendations
TAL Education analyst commentary  »

TAL Education price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UBFO

United Security Bank

$8.05

-0.05 (-0.62%)

12:21
04/27/17
04/27
12:21
04/27/17
12:21
Hot Stocks
United Security Bank resumes dividend at 5c per share, authorizes $3M buyback »

On April 25, the board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$909.29

1.67 (0.18%)

12:19
04/27/17
04/27
12:19
04/27/17
12:19
Technical Analysis
Amazon.com technical comments ahead of earnings »

The shares are trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 16

    May

  • 23

    May

FB

Facebook

$146.56

0.07 (0.05%)

12:18
04/27/17
04/27
12:18
04/27/17
12:18
Periodicals
Facebook to combat 'information operations' using fake accounts, Reuters reports »

Facebook is making an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.